We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of American Renal Associates Holdings, Inc. (“American Renal Associates” or the “Company”) (NYSE: ARA) to Innovative Renal Care, LLC (“Innovative Renal Care”). Under the terms of the deal, Innovative Renal Care will acquire American Renal Associates in an all cash transaction for $11.50 per share.
The American Renal Associates merger investigation concerns whether the Board of American Renal Associates has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.